Zura Bio Limited (ZURA)

Market Cap	156.69M
Revenue (ttm)	n/a
Net Income (ttm)	-65.43M
Shares Out	65.02M
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,368,708
Open	2.090
Previous Close	2.100
Day's Range	2.070 - 2.440
52-Week Range	0.970 - 5.070
Beta	-0.02
Analysts	Buy
Price Target	11.00 (+356.43%)
Earnings Date	Nov 6, 2025

About ZURA

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2022
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: ZURA
• Website: https://zurabio.com

Analyst Forecast

According to 9 analysts, the average rating for ZURA stock is "Buy." The 12-month stock price target is $11.0, which is an increase of 356.43% from the latest price.

Price Target

$11.0

(356.43% upside)

Analyst Consensus: Buy